Moreover, several impressive studies of the structure–activity relationships of these molecules have been reported in succession.17–20 Developing activators targeting STING has provided an impetus to cancer immunotherapy, and STING agonists with novel chemical entities are urgently required for propelling their application. The gene discussed is STING1; the disease is cancer.